Publication:
A practical and case-based approach to thrombocytopenia in cardiology practice

dc.contributor.coauthorN/A
dc.contributor.departmentKUH (Koç University Hospital)
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorMutluer, Ferit Onur
dc.contributor.kuauthorÖztürk, Erman
dc.contributor.schoolcollegeinstituteKUH (KOÇ UNIVERSITY HOSPITAL)
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-10T00:11:06Z
dc.date.issued2018
dc.description.abstractIn cardiology practice, anticoagulation and antiplatelet therapies are essential for most patients. As of yet, there is no high quality evidence regarding these treatments in thrombocytopenic patients, which continues to be an issue. Thrombocytopenia is defined as a platelet count of <150x10(9)/L and is classified as severe when the platelet count is <50x10(9)/L. Pseudothrombocytopenia, drug-induced thrombocytopenia, immune thrombocytopenia, heparin-induced thrombocytopenia, and thrombotic thrombocytopenic purpura are some of the main causes of thrombocytopenia. The current treatment suggestions are conservative, as a result of the lack of evidence, built on defensive treatment strategies and the fear of bleeding complications. Many patients with acute myocardial infarction with thrombocytopenia have undergone percutaneous coronary intervention successfully with adjunctive antiplatelet and anticoagulant use, as has been described in case reports. A risk-benefit ratio should be evaluated for antiplatelet therapy. In the relevant guidelines, while full dose low-molecular-weight heparin (LMWH) is recommended for patients with a thrombocyte count of >50x10(9)/L, a half-dose of LMWH is recommended in patients with thrombocytopenia between 25 and 50x10(9)/L. According to the current guidelines, avoiding antiplatelet and anticoagulant treatment should be restricted to patients with very severe thrombocytopenia (i.e., a platelet count <25x10(9)/L), but new data and recommendations are needed.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.indexedbyTR Dizin
dc.description.issue2
dc.description.openaccessYES
dc.description.publisherscopeNational
dc.description.sponsoredbyTubitakEuN/A
dc.description.volume46
dc.identifier.doi10.5543/tkda.2018.76968
dc.identifier.issn1016-5169
dc.identifier.scopus2-s2.0-85043271592
dc.identifier.urihttps://doi.org/10.5543/tkda.2018.76968
dc.identifier.urihttps://hdl.handle.net/20.500.14288/17426
dc.identifier.wos429379500013
dc.keywordsAnticoagulant
dc.keywordsAntiplatelet
dc.keywordsCardiology
dc.keywordsHeparin induced thrombotic thrombocytopenia
dc.keywordsImmune thrombocytopenic purpura
dc.keywordsThrombocytopenia
dc.language.isoeng
dc.publisherTurkish Soc Cardiology
dc.relation.ispartofTürk Kardiyoloji Derneği Arşivi-Archives of the Turkish Society of Cardiology
dc.subjectCardiac and Cardiovascular Systems
dc.titleA practical and case-based approach to thrombocytopenia in cardiology practice
dc.title.alternativeKardiyoloji pratiğinde trombositopeniye olgu bazlı ve pratik yaklaşım
dc.typeReview
dspace.entity.typePublication
local.contributor.kuauthorÖztürk, Erman
local.contributor.kuauthorMutluer, Ferit Onur
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit1KUH (KOÇ UNIVERSITY HOSPITAL)
local.publication.orgunit2KUH (Koç University Hospital)
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isParentOrgUnitOfPublication055775c9-9efe-43ec-814f-f6d771fa6dee
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery055775c9-9efe-43ec-814f-f6d771fa6dee

Files